The important differences between assessments by EUnetHTA and those by national health technology assessment (HTA) agencies are presented, and consideration is given to the potential implications for manufacturers of harmonizing HTA approaches to clinical assessment. Discussion points:
Introduction to the creation of EUnetHTA, and its current and potential future influence on European market access
Critical review of the key differences between a range of evidence domains, evidence requirements, approaches, and preferred methodologies used in assessments by EUnetHTA versus those used by HTA agencies in Germany (the G-BA), England and Wales (NICE), and France (the TC)
Examples of differences in approaches to assessing evidence between the agencies and EUnetHTA, as observed in past assessments
Summarization of the implications for the pharmaceutical industry in the EU of increased harmonization in HTA approaches to clinical assessment, via the EUnetHTA initiative.
Duration: 45 minutes. Available to watch on demand.
Ideal viewing: This on-demand webinar is essential viewing for all global, regional, and affiliate market access and HEOR teams. Please share this with your colleagues.
EUnetHTA joint clinical assessments: where have we come from and where are we going?
Privacy & Cookies Policy
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.